265 related articles for article (PubMed ID: 27712835)
1. Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases.
Sánchez-Bueno F; García-Pérez R; Claver Valderas MA; de la Peña Moral J; Frutos Esteban L; Ortiz Ruiz E; Fuster Quiñonero M; Parrilla Paricio P
Cir Esp; 2016 Nov; 94(9):511-517. PubMed ID: 27712835
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
[TBL] [Abstract][Full Text] [Related]
3. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
[TBL] [Abstract][Full Text] [Related]
4. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
5. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.
Pergolini I; Crippa S; Salgarello M; Belfiori G; Partelli S; Ruffo G; Pucci A; Zamboni G; Falconi M
Dig Liver Dis; 2018 Jan; 50(1):84-90. PubMed ID: 29017830
[TBL] [Abstract][Full Text] [Related]
6. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
7. Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma.
Yamamoto T; Sugiura T; Mizuno T; Okamura Y; Aramaki T; Endo M; Uesaka K
Ann Surg Oncol; 2015 Feb; 22(2):677-84. PubMed ID: 25190125
[TBL] [Abstract][Full Text] [Related]
8. The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.
Jung W; Jang JY; Kang MJ; Chang YR; Shin YC; Chang J; Kim SW
HPB (Oxford); 2016 Jan; 18(1):57-64. PubMed ID: 26776852
[TBL] [Abstract][Full Text] [Related]
9. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
[TBL] [Abstract][Full Text] [Related]
10. Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma.
Wang L; Dong P; Wang W; Li M; Hu W; Liu X; Tian B
Medicine (Baltimore); 2020 Mar; 99(11):e19504. PubMed ID: 32176094
[TBL] [Abstract][Full Text] [Related]
11. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
[TBL] [Abstract][Full Text] [Related]
12. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of preoperative fluorodeoxyglucose positron emission tomography/computed tomography in patients with potentially resectable pancreatic cancer.
Omiya Y; Ichikawa S; Satoh Y; Motosugi U; Nakajima N; Onishi H
Abdom Radiol (NY); 2018 Dec; 43(12):3381-3389. PubMed ID: 30043215
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (
Matsumoto T; Okabe H; Yamashita YI; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
Surg Today; 2019 Jan; 49(1):21-26. PubMed ID: 30128759
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.
Chirindel A; Alluri KC; Chaudhry MA; Wahl RL; Pawlik TM; Herman JM; Subramaniam RM
AJR Am J Roentgenol; 2015 May; 204(5):1093-9. PubMed ID: 25905947
[TBL] [Abstract][Full Text] [Related]
16. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.
Burge ME; O'Rourke N; Cavallucci D; Bryant R; Francesconi A; Houston K; Wyld D; Eastgate M; Finch R; Hopkins G; Thomas P; Macfarlane D
HPB (Oxford); 2015 Jul; 17(7):624-31. PubMed ID: 25929273
[TBL] [Abstract][Full Text] [Related]
18. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.
Ariake K; Motoi F; Shimomura H; Mizuma M; Maeda S; Terao C; Tatewaki Y; Ohtsuka H; Fukase K; Masuda K; Hayashi H; Takadate T; Naitoh T; Taki Y; Unno M
J Gastrointest Surg; 2018 Feb; 22(2):279-287. PubMed ID: 29119533
[TBL] [Abstract][Full Text] [Related]
19. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
20. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
